SystemOne Partners with BluSense Diagnostics
For Immediate Release
SystemOne Partners with BluSense Diagnostics
USAID Grant Recipients Collaborate for Rapid Fever Detection and Response
Boston, MA – June 12, 2017 -- SystemOne, the leader in global health disease surveillance and response, recently announced its partnership with BluSense Diagnostics for their upcoming clinical trials in Brazil and Malaysia. For this project, SystemOne will provide the connectivity solution to securely move critical healthcare data from BluSense’s diagnostic test instruments to local clinicians and health information systems.
Both companies are recipients of the USAID Grand Challenge for Development Grant which supports solutions combatting Zika and future threats. SystemOne and BluSense will support each other’s objectives to communicate disease outbreak data for Dengue and Zika across the world.
The project will integrate data from BluSense’s BluBoxTM diagnostic device into Aspect,® SystemOne's data management platform. SystemOne is also developing an interface for BluSense customers to easily view and analyze disease-related data. This disease intelligence solution will be piloted with the BluBox Dengue assay in field studies in Malaysia and Brazil.
BluSense, based in Denmark, is developing a new way to test for the Dengue virus using a single drop of blood. In addition to the BluBoxTM and the Dengue Assay, the USAID Challenge Grant supports the company in developing an assay which can diagnose the presence of Zika infection. The collaboration with SystemOne supports a long-term goal to provide real-time diagnostic data to health professionals and first responders.
“We see a natural alignment with BluSense as they prepare to launch the BluBoxTM, along with the Dengue and Zika tests, in markets where SystemOne’s disease intelligence networks already deliver real-time disease information,” notes Chris Macek, CEO at SystemOne. “By collaborating on the upcoming studies in Southeast Asia and Latin America, both companies bring core competencies to enable rapid detection and response to pandemic-prone diseases in high-risk regions of the world.”
"While our instrument generates critical data, we needed a partner to help us move, parse and channel the data to the right places to make the most difference," said Filippo Bosco, CEO, BluSense Diagnostics. "SystemOne, with its existing experience in dozens of countries, was the ideal partner to help us understand the best use cases for real-time information and for aggregated data, and how to make the data flow in the most effective and least costly manner."
BluSense is a biotech spin-out from the Technical University of Denmark (DTU) and it is a global-born startup built around its core IP, a patented novel immunoassay detection technology based on the use of nanoparticles and low-cost and mass-production compatible electronics of Blu-Ray players.
The laboratories in Denmark are fully equipped with state-of-the-art technology for development of BSD products. Its Copenhagen HQ consists of highly skilled technical (biochemists, engineers and technicians) and non-technical (marketing, accounting, regulatory, operations) personnel coming from 9 countries. BluSense Taiwan employs 8 former engineers of QSI who have on average 11 years of experience in developing hardware for optical media, plus a local manager.
The company's vision is to provide affordable and accurate blood testing for infectious disease diagnostics. Its mission is to build a sustainable business through large-scale deployment of accurate and affordable point-of-care platforms for diagnosing infectious diseases and to create bio-sensing products based on innovative micro and nanotechnologies.
Founded in Massachusetts in 2012, SystemOne focuses on producing game-changing big data solutions for disease surveillance and response. SystemOne has offices in Springfield and Boston, MA and Johannesburg, South Africa. SystemOne’s flagship product, GxAlert, is a software platform that collects and shares data to:
- alert health officials when positive disease results are detected,
- reduce time to treatment by getting patients enrolled earlier,
- save health systems millions of dollars in inventory waste,
- provide real-time and complete disease surveillance monitoring capabilities,
- serve approximately 1,500 tuberculosis and Ebola labs and clinics,
- send over 30,000 messages and alerts every month,
- provide simple, user-friendly data visualizations to accelerate treatment and streamline health care systems in over 35 countries.
GxAlert is currently available in seven languages: English, Portuguese, Kiswahili, Russian, Vietnamese, German and French.
The company’s new disease intelligence software, Aspect®, addresses additional infectious diseases, including Ebola, HIV, Malaria, Hepatitis C and more on a host of diagnostic devices.